Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Cases. Apr 26, 2026; 14(12): 119171
Published online Apr 26, 2026. doi: 10.12998/wjcc.v14.i12.119171
Published online Apr 26, 2026. doi: 10.12998/wjcc.v14.i12.119171
Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review
Chris Alphonse, Department of Internal Medicine, Diana Princess of Wales Hospital, Grimsby DN33 2BA, North East Lincolnshire, United Kingdom
Muhammad Irfan, Department of Internal Medicine, Shrewsbury and Telford Hospital Trust, Shrewsbury SY3 8XQ, Shropshire, United Kingdom
Sergio Camilo Torres Céspedes, Universidad Nacional de Colombia, Bogota 111321, Bogotá, Colombia
Chisom Nwanejuafor, Department of Internal Medicine, Northampton General Hospital NHS Trust, Northampton NN1 5BD, Northamptonshire, United Kingdom
Kashfia Nayeem, Windsor University School of Medicine, Chicago, IL 60449, United States
Elias Hertan, Medical University of Varna, Varna 9002, Bulgaria
Vrinda Mohan, University of Birmingham, Dubai 341799, Dubayy, United Arab Emirates
Haripriya Gupta, Department of Internal Medicine, Royal Shrewsbury Hospital, Shrewsbury SY3 8XQ, Shropshire, United Kingdom
Noor Ul Ain Fatima, Bahria University Health Science Campus, Karachi 75200, Sindh, Pakistan
Luis Adrian Guadarrama Mendoza, Department of Internal Medicine, Hospital Regional de Alta Especialidad de Zumpango, Zumpango 55600, México, Mexico
Azkah Sardar, Department of Public Health, MBCHB University of Glasgow, Honorary Clinical status from University of Edinburgh, Edinburgh G12 8QQ, United Kingdom
Alexander Michael Diaz, St. George’s University, New York, NY 11739, United States
Inshal Jawed, Department of Medicine, Dow University of Health Sciences, Karachi 75350, Sindh, Pakistan
Co-first authors: Chris Alphonse and Muhammad Irfan.
Author contributions: Alphonse C, Irfan M, and Jawed I designed the research study; Alphonse C, Irfan M, Torres Céspedes SC, Nwanejuafor C, Nayeem K, Hertan E, Mohan V, Gupta H, Fatima NUA, Guadarrama Mendoza LA, Sardar A, and Diaz AM performed the research and data acquisition; Torres Céspedes SC, Mohan V, and Sardar A contributed to analytic methods and evidence synthesis tools; Alphonse C, Irfan M, and Jawed I analyzed the data and wrote the manuscript; Alphonse C and Irfan M contributed equally to this work and are co-first authors; and all authors critically revised the manuscript and have read and approved the final version.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Check-list.
Corresponding author: Inshal Jawed, MBBS, Department of Medicine, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com
Received: January 21, 2026
Revised: February 26, 2026
Accepted: March 18, 2026
Published online: April 26, 2026
Processing time: 84 Days and 23.9 Hours
Revised: February 26, 2026
Accepted: March 18, 2026
Published online: April 26, 2026
Processing time: 84 Days and 23.9 Hours
Core Tip
Core Tip: An updated systematic review of 28 studies (10847 patients) shows that the efficacy of lebrikizumab, a high-affinity anti-interleukin-13 monoclonal antibody, is equivalent to that of dupilumab and superior to that of tralokinumab in moderate-to-severe atopic dermatitis (AD). The results showed that lebrikizumab performs better than baricitinib and has efficacy comparable to that of most Janus kinase inhibitors. It also has a better safety profile, with no boxed warnings. Data from real-world and extension studies confirm sustained efficacy. Evidence of moderate to high quality suggests lebri